Search company, investor...
Evonik company logo


Founded Year




Total Raised


Date of IPO


About Evonik

Evonik (FWB: EVK) is an industrial corporation that offers the production of chemicals. It caters to sectors such as the nutrition and care, resource efficiency, performance materials, and technology and infrastructure segments. The company also specializes in power generation from hard coal and renewable energies and in real estate, as a private-sector housing company that focuses on letting housing to private households. The company was founded in 1847 and is based in Essen, Germany.

Headquarters Location

Rellinghauser Strasse 1-11

Essen, 45128,


+49 201 177-01

Missing: Evonik's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Evonik's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Evonik

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Evonik in 1 CB Insights research brief, most recently on Jul 29, 2020.

Evonik Patents

Evonik has filed 871 patents.

The 3 most popular patent topics include:

  • Polymers
  • Chemical processes
  • Commodity chemicals
patents chart

Application Date

Grant Date


Related Topics




Concrete, Building insulation materials, Thermal protection, Insulators, Materials


Application Date


Grant Date



Related Topics

Concrete, Building insulation materials, Thermal protection, Insulators, Materials



Latest Evonik News

EnBW Energie Baden Württemberg : Evonik and EnBW sign another long-term purchase agreement for power supply from the “He Dreiht” offshore wind farm

Feb 2, 2023

02/02/2023 | 05:00am EST Message : *Required fields Karlsruhe/Essen. Even more wind energy from the North Sea: Evonik has extended its cooperation with EnBW and signed a second power purchase agreement from the planned "He Dreiht" offshore wind farm. A first power purchase agreement (PA) was already concluded to purchase 100 megawatts (MW) last year. The second agreement now adds a further 50 MW. As a result, the specialty chemicals company should be able to cover more than a third of its power requirements in Europe from 2026 onwards. The term of the second tranche is also 15 years. Expansion of renewable capacity using the market instead of funding "Extending the cooperation with EnBW is the next step on our way to significantly reducing our dependence on fossil fuels and their price fluctuations," says Christian Kullmann, CEO of Evonik. Evonik announced the first tranche of the PPA with EnBW back in November. Further supply contracts for green electricity directly from the producer are currently in the planning stage. "We are fully determined to increase the share of green electricity in our energy mix and thus further reduce greenhouse gas emissions," says Kullmann. "We are building the 'He Dreiht' wind farm with money raised on the market rather than through state funding. Long-term power purchase agreements are the right way for us to expand renewable capacity," explains EnBW board member Georg Stamatelopoulos. "PPAs have established themselves as a key instrument in the energy transition. It is therefore all the more important that state intervention in the market does not represent any kind of permanent solution. This could have a negative impact on the willingness to invest and hamper the further expansion of renewable capacity. We are delighted to be able to help Evonik to reduce carbon emissions with another package of offshore wind energy. By doing so, we are gradually helping to decarbonize the industrial sector," he adds. Companies are increasingly opting for PPAs to improve sustainability "Last year, we saw a significant increase in inquiries from medium-sized and large companies," says Stamatelopoulos. "This shows that there is considerable interest among companies in using PPAs to consistently pursue their own sustainability goals. It represents a significant contribution to the energy transition and we can only achieve it together." "At present, 27 percent of Evonik's externally purchased electricity worldwide already comes from renewable sources. The two PPA tranches secured with EnBW will significantly increase this figure to around 50 percent," says Thomas Wessel, management board member responsible for sustainability at Evonik. "At the same time, the cooperation will reduce Evonik's Scope 2 emissions, i.e., emissions attributable to externally purchased power, by 150,000 metric tons of CO₂ per year," says Wessel. 900 MW EnBW offshore wind farm set to enter operation in 2025 The "He Dreiht" wind farm will be built about 90 kilometers northwest of Borkum and around 110 kilometers west of Helgoland and is scheduled to enter operation at the end of 2025. In 2017, EnBW secured the contract in the first offshore tendering process in Germany with a zero-cent bid, ushering in a new trend on the offshore market. The offshore wind farm being built without state funding is currently one of Europe's biggest energy transition projects. Turbines with an output of 15 megawatts are set to be used for the first time here. EnBW is planning to make the final investment decision in the first quarter of 2023. About Evonik Evonik is one of the world's leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. Around 33,000 employees work together for a common purpose: We want to improve life, today and tomorrow. Legal notice Insofar as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. About EnBW With over 26,000 employees, EnBW is one of the largest energy companies in Germany and Europe. It supplies around 5.5 million customers with electricity, gas, water as well as services and products in the areas of infrastructure and energy. The expansion of renewable energies is a cornerstone of the growth strategy and a focus of investment. EnBW will invest around four billion euros in the further expansion of wind and solar energy between 2021 and 2025. By the end of 2025, more than half of the generation portfolio is set to consist of renewable energies. Furthermore, the expansion of renewable energies is an important part of EnBW's Sustainability Agenda as the company heads towards climate neutrality by 2035. EnBW has been actively involved in PPA matters in Germany from the very beginning: In 2019, the company signed the first PPA of its kind in Germany with Energiekontor. In December 2021, it announced the first supply contract with Fraport AG for 85 megawatts of electricity from the "He Dreiht" offshore wind farm. Evonik followed in 2022 with 100 MW and Salzgitter with 50 MW. Attachments

Evonik Frequently Asked Questions (FAQ)

  • When was Evonik founded?

    Evonik was founded in 1847.

  • Where is Evonik's headquarters?

    Evonik's headquarters is located at Rellinghauser Strasse 1-11, Essen.

  • What is Evonik's latest funding round?

    Evonik's latest funding round is IPO.

  • How much did Evonik raise?

    Evonik raised a total of $4.488B.

  • Who are the investors of Evonik?

    Investors of Evonik include Temasek and CVC Capital Partners.

  • Who are Evonik's competitors?

    Competitors of Evonik include Lakril Technologies and 4 more.

Compare Evonik to Competitors


Hymeth develops a non-precious metal electro catalyst intended to efficiently split water into hydrogen and oxygen to produce methane, a sustainable alternative to fossil natural gas. The company's product beauty can convert excess renewable electrical energy into hydrogen for easier storage or refueling fuel cell vehicles with an objective to replace the standard liquid petroleum gas used for cooking in most countries in the world with this methane, enabling users to get safer and more environmentally friendly fuel than existing alternatives.


Celldrive offers a bioink platform for creating living tissues on demand. Its animal component-free formulation mimics the extracellular matrix maximizing the cell viability of embedded cells and 3D resolution.


MEDICAL IP develops medical imaging and its 3D visualization applications for medical situations such as surgery, medical education, and communication between patient and medical doctors. MEDICAL IP's products include MEDIP, a medical imaging software offering everything from image segmentation to virtual-augmented reality 3D visualization; and ANATDEL, an advanced 3D printing technology which is similar to real organs in texture, feeling, and elasticity. The company aims to solve and visualize solutions for internal organ structure, tumor and cancer behavior, supporting doctors and surgeons for diagnoses and advance surgical planning.


T&R BIOFAB (티앤알바이오팹) is focused on tissue engineering & regenerative medicine and bio-fabrication. The company manufactures bioresorbable scaffolds that aid in regeneration and reconstruction of tissues and organs using 3D printing technology.

ROKIT Healthcare

ROKIT Healthcare is a global regenerative solutions company that provides an autologous organ regeneration platform using proprietary 3D bio-fabrication technologies. The company’s products include 3DISON, a professional desktop 3D printer, and DR. INVIVO, a sterile, all-in-one 4D organ regenerator that is used to regenerate skin as a treatment for diabetic foot ulcers, negating the need for amputation and skin grafting.

Sunp Biotech Logo
Sunp Biotech

Sunp Biotech is a research and manufacturing company specialized in 3D bio-printing and tissue engineering.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.